Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES

Author(s):: Szarek, M.; Reijnders, E. (0000-0003-3520-5869); Steg, P.G.; Jukema, J.W. (0000-0002-3246-8359); Schwertfeger, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Fazio, S.; Garon, G.; Goodman, S.G.; Harrington, R.A.; White, H.D.; Zeiher, A.M.; Cobbaert, C.; Schwartz, G.G.

Published: 2024
Publication type: Article / Letter to editor

Date issued: 2024-03-19
Language: English
Is part of: European Journal of Preventive Cardiology (2024), Vol. 31, no. 10, p. e75-e78
hdl: 1887/4197245
doi: 10.1093/eurjpc/zwae110
URL: https://academic.oup.com/eurjpc/article/31/10/e75/7631469